Variability in detection of SARS-CoV-2-specific antibody responses following mild infection : a prospective multicentre cross-sectional study, London, United Kingdom, 17 April to 17 July 2020
IntroductionImmunoassays targeting different SARS-CoV-2-specific antibodies are employed for seroprevalence studies. The degree of variability between immunoassays targeting anti-nucleocapsid (anti-NP; the majority) vs the potentially neutralising anti-spike antibodies (including anti-receptor-binding domain; anti-RBD), particularly in mild or asymptomatic disease, remains unclear.AimsWe aimed to explore variability in anti-NP and anti-RBD antibody detectability following mild symptomatic or asymptomatic SARS-CoV-2 infection and analyse antibody response for correlation with symptomatology.MethodsA multicentre prospective cross-sectional study was undertaken (April-July 2020). Paired serum samples were tested for anti-NP and anti-RBD IgG antibodies and reactivity expressed as binding ratios (BR). Multivariate linear regression was performed analysing age, sex, time since onset, symptomatology, anti-NP and anti-RBD antibody BR.ResultsWe included 906 adults. Antibody results (793/906; 87.5%; 95% confidence interval: 85.2-89.6) and BR strongly correlated (ρ = 0.75). PCR-confirmed cases were more frequently identified by anti-RBD (129/130) than anti-NP (123/130). Anti-RBD testing identified 83 of 325 (25.5%) cases otherwise reported as negative for anti-NP. Anti-NP presence (+1.75/unit increase; p < 0.001), fever (≥ 38°C; +1.81; p < 0.001) or anosmia (+1.91; p < 0.001) were significantly associated with increased anti-RBD BR. Age (p = 0.85), sex (p = 0.28) and cough (p = 0.35) were not. When time since symptom onset was considered, we did not observe a significant change in anti-RBD BR (p = 0.95) but did note decreasing anti-NP BR (p < 0.001).ConclusionSARS-CoV-2 anti-RBD IgG showed significant correlation with anti-NP IgG for absolute seroconversion and BR. Higher BR were seen in symptomatic individuals, particularly those with fever. Inter-assay variability (12.5%) was evident and raises considerations for optimising seroprevalence testing strategies/studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin - 27(2022), 4 vom: 27. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pallett, Scott Jc [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 01.02.2022 Date Revised 05.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2807/1560-7917.ES.2022.27.4.2002076 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336209703 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336209703 | ||
| 003 | DE-627 | ||
| 005 | 20240405232809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2807/1560-7917.ES.2022.27.4.2002076 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM336209703 | ||
| 035 | |a (NLM)35086612 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pallett, Scott Jc |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Variability in detection of SARS-CoV-2-specific antibody responses following mild infection |b a prospective multicentre cross-sectional study, London, United Kingdom, 17 April to 17 July 2020 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2022 | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a IntroductionImmunoassays targeting different SARS-CoV-2-specific antibodies are employed for seroprevalence studies. The degree of variability between immunoassays targeting anti-nucleocapsid (anti-NP; the majority) vs the potentially neutralising anti-spike antibodies (including anti-receptor-binding domain; anti-RBD), particularly in mild or asymptomatic disease, remains unclear.AimsWe aimed to explore variability in anti-NP and anti-RBD antibody detectability following mild symptomatic or asymptomatic SARS-CoV-2 infection and analyse antibody response for correlation with symptomatology.MethodsA multicentre prospective cross-sectional study was undertaken (April-July 2020). Paired serum samples were tested for anti-NP and anti-RBD IgG antibodies and reactivity expressed as binding ratios (BR). Multivariate linear regression was performed analysing age, sex, time since onset, symptomatology, anti-NP and anti-RBD antibody BR.ResultsWe included 906 adults. Antibody results (793/906; 87.5%; 95% confidence interval: 85.2-89.6) and BR strongly correlated (ρ = 0.75). PCR-confirmed cases were more frequently identified by anti-RBD (129/130) than anti-NP (123/130). Anti-RBD testing identified 83 of 325 (25.5%) cases otherwise reported as negative for anti-NP. Anti-NP presence (+1.75/unit increase; p < 0.001), fever (≥ 38°C; +1.81; p < 0.001) or anosmia (+1.91; p < 0.001) were significantly associated with increased anti-RBD BR. Age (p = 0.85), sex (p = 0.28) and cough (p = 0.35) were not. When time since symptom onset was considered, we did not observe a significant change in anti-RBD BR (p = 0.95) but did note decreasing anti-NP BR (p < 0.001).ConclusionSARS-CoV-2 anti-RBD IgG showed significant correlation with anti-NP IgG for absolute seroconversion and BR. Higher BR were seen in symptomatic individuals, particularly those with fever. Inter-assay variability (12.5%) was evident and raises considerations for optimising seroprevalence testing strategies/studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Diagnostics | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 700 | 1 | |a Jones, Rachael |e verfasserin |4 aut | |
| 700 | 1 | |a Abdulaal, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Pallett, Mitchell A |e verfasserin |4 aut | |
| 700 | 1 | |a Rayment, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Aatish |e verfasserin |4 aut | |
| 700 | 1 | |a Denny, Sarah J |e verfasserin |4 aut | |
| 700 | 1 | |a Mughal, Nabeela |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Rosadas de Oliveira, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Pantelidis, Panagiotis |e verfasserin |4 aut | |
| 700 | 1 | |a Randell, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Toumazou, Christofer |e verfasserin |4 aut | |
| 700 | 1 | |a O'Shea, Matthew K |e verfasserin |4 aut | |
| 700 | 1 | |a Tedder, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a McClure, Myra O |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Gary W |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Luke Sp |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin |d 1995 |g 27(2022), 4 vom: 27. Jan. |w (DE-627)NLM115683283 |x 1560-7917 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:4 |g day:27 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2807/1560-7917.ES.2022.27.4.2002076 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 4 |b 27 |c 01 | ||